Ambrx | protein therapeutics - antibody drug conjugates

A Convergence of Chemistry And Biology To Create Better Medicine

Learn More

WHAT WE BELIEVE

Ambrx is developing innovative protein therapeutics that preserve potency, reduce dosing frequency and improve homogeneity of the drug substance.

Learn More

Our Technology

Ambrx is harnessing the power of an expanded genetic code to optimize the performance of therapeutic proteins, peptides, bi-specifics and full length antibody conjugates

Learn More

PIPELINE

Ambrx has a number of highly differentiated product candidates at various stages of development in its pipeline, with a focus on “best in class” biopharmaceutical product opportunities.

Learn More

Partnerships

Partnerships for Next Generation Biologics

Learn More

News

Apr 25, 2017

Primary endpoint of significant reduction in liver fat achieved following 16 weeks of treatment with...

A Convergence of Chemistry And Biology To Create Better Medicine

WHAT WE BELIEVE

Our Technology

PIPELINE

Partnerships

News

Bristol-Myers Squibb’s BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial

Ambrx closes $45M round of financing

Ambrx and Zhejiang Medicine Co. Ltd initiated ARX788 First-In-Human phase I clinical trial in cancer patients